OBJECTIVES: To analyze the relationships among socioeconomic status (SES), race, and the clinical parameters of patients undergoing radical prostatectomy (RP) in an equal access health care system. METHODS: The Department of Defense Center for Prostate Disease Research longitudinal prostate cancer database from multiple military institutions was used to analyze the clinical, pathologic, and outcome data of 1058 patients with localized (Stage T2c or lower) prostate cancer and a preoperative prostate-specific antigen (PSA) level of 20 ng/mL or less who underwent RP between January 1987 and December 1997. Military rank (officer versus enlisted) was used as a surrogate measure of SES. RESULTS: The percentage of patients with pathologic Gleason grade 7 or greater prostate cancer was higher in enlisted (45%) than in officer (37%) patients (P = 0. 021). However, no difference was found between these groups with respect to pathologic stage or biochemical recurrence rates. African Americans presented at a younger age (P = 0.003), with a higher pretreatment PSA level (P = 0.001), and demonstrated higher biochemical recurrence rates than other ethnic groups (P = 0.037). The Cox proportional hazards analysis showed that a lower SES (P = 0.010) but not African American race (P = 0.696) was an independent predictor of a higher grade (Gleason grade 7 or higher) cancer. However, biochemical progression was more common in African American men (P = 0.035) and was not related to SES (P = 0.883). CONCLUSIONS: In an equal access health care system, patients of lower SES presented with higher grade prostate cancer at the time of RP. However, only African American race predicted biochemical progression after RP.
OBJECTIVES: To analyze the relationships among socioeconomic status (SES), race, and the clinical parameters of patients undergoing radical prostatectomy (RP) in an equal access health care system. METHODS: The Department of Defense Center for Prostate Disease Research longitudinal prostate cancer database from multiple military institutions was used to analyze the clinical, pathologic, and outcome data of 1058 patients with localized (Stage T2c or lower) prostate cancer and a preoperative prostate-specific antigen (PSA) level of 20 ng/mL or less who underwent RP between January 1987 and December 1997. Military rank (officer versus enlisted) was used as a surrogate measure of SES. RESULTS: The percentage of patients with pathologic Gleason grade 7 or greater prostate cancer was higher in enlisted (45%) than in officer (37%) patients (P = 0. 021). However, no difference was found between these groups with respect to pathologic stage or biochemical recurrence rates. African Americans presented at a younger age (P = 0.003), with a higher pretreatment PSA level (P = 0.001), and demonstrated higher biochemical recurrence rates than other ethnic groups (P = 0.037). The Cox proportional hazards analysis showed that a lower SES (P = 0.010) but not African American race (P = 0.696) was an independent predictor of a higher grade (Gleason grade 7 or higher) cancer. However, biochemical progression was more common in African American men (P = 0.035) and was not related to SES (P = 0.883). CONCLUSIONS: In an equal access health care system, patients of lower SES presented with higher grade prostate cancer at the time of RP. However, only African American race predicted biochemical progression after RP.
Authors: David I Chu; Daniel M Moreira; Leah Gerber; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Brian M Rivers; Euna M August; Gwendolyn P Quinn; Clement K Gwede; Julio M Pow-Sang; B Lee Green; Paul B Jacobsen Journal: J Cancer Educ Date: 2012-06 Impact factor: 2.037
Authors: M Bonet; A Merglen; G Fioretta; E Rapiti; I Neyroud-Caspar; R Zanetti; R Miralbell; C Bouchardy Journal: Clin Transl Oncol Date: 2009-05 Impact factor: 3.405
Authors: Ingrid Oakley-Girvan; Laurence N Kolonel; Richard P Gallagher; Anna H Wu; Anna Felberg; Alice S Whittemore Journal: Am J Public Health Date: 2003-10 Impact factor: 9.308
Authors: Rebecca E Scully; Andrew J Schoenfeld; Wei Jiang; Stuart Lipsitz; Muhammad Ali Chaudhary; Peter A Learn; Tracey Koehlmoos; Adil H Haider; Louis L Nguyen Journal: JAMA Surg Date: 2018-01-01 Impact factor: 14.766
Authors: Laurens Holmes; Wenyaw Chan; Zhidong Jiang; Doriel Ward; E James Essien; Xianglin L Du Journal: Cancer Control Date: 2009-04 Impact factor: 3.302
Authors: Lionel L Bañez; Martha K Terris; William J Aronson; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-31 Impact factor: 4.254
Authors: Curtis Bryant; Bradford S Hoppe; Randal H Henderson; Romaine C Nichols; William M Mendenhall; Tamara L Smith; Christopher G Morris; Christopher R Williams; Zhong Su; Zuofeng Li; Nancy P Mendenhall Journal: Int J Part Ther Date: 2017-07-11